In Utero Development and Immunosurveillance of B Cell Acute Lymphoblastic Leukemia.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic models without primary empirical data
PubMed 35294722 · doi:10.1007/s11864-022-00963-3
What was done
This narrative review synthesized current literature on the prenatal origins of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), the genetic and environmental 'second hits' that drive progression, and the role of host immune surveillance (specifically natural killer and T helper cells) in containing preleukemic clones.
What was found
The abstract reports no numerical findings or statistical measures. It describes a two-step oncogenic model where silent preleukemic clones arise in utero through germline predisposition and acquired somatic mutations, while overt leukemia manifests postnatally following secondary triggers, such as abnormal or dysregulated immune responses to infection. The review highlights that immune surveillance may normally restrain these clones and discusses early immune modulation as a theoretical strategy for leukemia prevention.
Why it matters
Framing pediatric ALL as a multi-step disease initiated before birth highlights a therapeutic window where boosting natural immune surveillance could potentially eradicate preleukemic clones before overt malignancy develops.
Limits
The abstract provides no primary data, systematic search protocol, or quantitative synthesis. Concepts regarding immune-mediated prevention and the specific triggers of postnatal clonal expansion remain theoretical and require prospective experimental and clinical validation.
Cited by
- supports Certain types of cancers, such as childhood leukemias, peak in incidence during childhood rather than in later stages of life.